Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACVBP + rituximab
- Development stage
- Phase 3
- Lead developer
- Groupe d’Etude des Lymphomes de l’Adulte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
ACVBP + rituximab is an intensified immunochemotherapy regimen combining the polychemotherapy ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) with the anti-CD20 monoclonal antibody rituximab, used primarily for diffuse large B-cell lymphoma (DLBCL). In randomized trials, adding rituximab to ACVBP improved event-free and progression-free survival versus ACVBP alone in young patients with localized low-risk DLBCL, and R-ACVBP improved survival compared with standard R-CHOP in patients aged 18–59 with low-intermediate IPI risk, albeit with increased hematologic toxicity. Mechanistically, rituximab mediates B-cell depletion via CD20-dependent cytotoxicity (CDC, ADCC, apoptosis), while ACVBP components provide cytotoxic chemotherapy targeting DNA replication/repair and microtubules.
- Other names
- R-ACVBPrituximab + ACVBP
02
Targets
CD20 (B-lymphocyte antigen CD20)DNATOP2A (DNA topoisomerase II)MicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ACVBP + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACVBP + rituximab.